Reports Q1 revenue $139.29M, consensus $144.46M. Cash, cash equivalents, and marketable debt securities were $563M as of March 31, which reflects cash payments made during Q1 of 2025 of $30M for a GTX-102 Phase 3 study milestone and $15M for an Evkeeza sales milestone, both achieved in Q4 of 2024. Net cash used in operations for the quarter ended March 31 was $166M and includes the payment of annual bonuses and a $30M cash payment for the GTX-102 development milestone.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- RARE Upcoming Earnings Report: What to Expect?
- RBC sees Makary interview as potentially positive for biotech stocks
- Ultragenyx price target lowered to $80 from $83 at BofA
- Ultragenyx price target raised to $117 from $104 at JPMorgan